Literature DB >> 12745016

Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration.

Peter Bernhardt1, Lars Kölby, Viktor Johanson, Ola Nilsson, Håkan Ahlman, Eva Forssell-Aronsson.   

Abstract

In nude mice carrying the human carcionoid GOT1 different amounts of (111)In-DTPA-Phe(1)-octreotide and routes of administration were studied in relation to uptake in tumor and normal organs. The relative organ uptake varied with given amount; highest in tumor after 0.1 and 1 microg and lowest in muscle, heart and blood after 0.1 microg. The uptake decreased in lungs and spleen with higher amounts of (111)In-DTPA-Phe(1)-octreotide. In all organs studied the tumor-to-normal-tissue activity concentration ratio was maximal at 0.1 and 1 microg, but route of administration influenced the uptake only little.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745016     DOI: 10.1016/s0969-8051(02)00417-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

1.  Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF.

Authors:  Heewa Kareem; Karl Sandström; Ronny Elia; Lars Gedda; Matti Anniko; Hans Lundqvist; Marika Nestor
Journal:  Tumour Biol       Date:  2010-01-30

2.  Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

Authors:  Vladimir Tolmachev; Helena Wållberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-11       Impact factor: 9.236

3.  Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount.

Authors:  Mark W Konijnenberg; Wout A P Breeman; Erik de Blois; Ho Sze Chan; Otto C Boerman; Peter Laverman; Petra Kolenc-Peitl; Marleen Melis; Marion de Jong
Journal:  EJNMMI Res       Date:  2014-08-30       Impact factor: 3.138

4.  Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice.

Authors:  Johan Spetz; Britta Langen; Nils Rudqvist; Toshima Z Parris; Khalil Helou; Ola Nilsson; Eva Forssell-Aronsson
Journal:  BMC Cancer       Date:  2017-08-08       Impact factor: 4.430

5.  Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography.

Authors:  Iulia Dude; Zhengxing Zhang; Julie Rousseau; Navjit Hundal-Jabal; Nadine Colpo; Helen Merkens; Kuo-Shyan Lin; François Bénard
Journal:  EJNMMI Radiopharm Chem       Date:  2017-04-17

6.  Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model.

Authors:  Mikael Elvborn; Emman Shubbar; Eva Forssell-Aronsson
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

Review 7.  Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumours: a Systematic Literature Review.

Authors:  Katrina Clair Cockburn; Zaher Toumi; Alison Mackie; Peter Julyan
Journal:  J Gastrointest Surg       Date:  2021-09-10       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.